Cardiol Therapeutics (CRDL) Competitors $1.08 -0.01 (-0.46%) As of 01:36 PM Eastern This is a fair market value price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesOwnershipSEC FilingsShort InterestTrendsBuy This Stock CRDL vs. YMAB, VIGL, ATXS, FULC, ABEO, INBX, ADCT, CTMX, ALDX, and BNTCShould you be buying Cardiol Therapeutics stock or one of its competitors? The main competitors of Cardiol Therapeutics include Y-mAbs Therapeutics (YMAB), Vigil Neuroscience (VIGL), Astria Therapeutics (ATXS), Fulcrum Therapeutics (FULC), Abeona Therapeutics (ABEO), Inhibrx Biosciences (INBX), ADC Therapeutics (ADCT), CytomX Therapeutics (CTMX), Aldeyra Therapeutics (ALDX), and Benitec Biopharma (BNTC). These companies are all part of the "pharmaceutical products" industry. Cardiol Therapeutics vs. Its Competitors Y-mAbs Therapeutics Vigil Neuroscience Astria Therapeutics Fulcrum Therapeutics Abeona Therapeutics Inhibrx Biosciences ADC Therapeutics CytomX Therapeutics Aldeyra Therapeutics Benitec Biopharma Y-mAbs Therapeutics (NASDAQ:YMAB) and Cardiol Therapeutics (NASDAQ:CRDL) are both small-cap medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their earnings, risk, valuation, profitability, dividends, analyst recommendations, media sentiment and institutional ownership. Which has better valuation and earnings, YMAB or CRDL? Cardiol Therapeutics has lower revenue, but higher earnings than Y-mAbs Therapeutics. Y-mAbs Therapeutics is trading at a lower price-to-earnings ratio than Cardiol Therapeutics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioY-mAbs Therapeutics$87.68M4.44-$29.67M-$0.50-17.15Cardiol TherapeuticsN/AN/A-$26.77M-$0.34-3.19 Is YMAB or CRDL more profitable? Cardiol Therapeutics has a net margin of 0.00% compared to Y-mAbs Therapeutics' net margin of -26.03%. Y-mAbs Therapeutics' return on equity of -24.60% beat Cardiol Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Y-mAbs Therapeutics-26.03% -24.60% -18.89% Cardiol Therapeutics N/A -232.26%-158.19% Do insiders & institutionals hold more shares of YMAB or CRDL? 70.9% of Y-mAbs Therapeutics shares are owned by institutional investors. Comparatively, 12.5% of Cardiol Therapeutics shares are owned by institutional investors. 19.7% of Y-mAbs Therapeutics shares are owned by company insiders. Comparatively, 5.3% of Cardiol Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth. Does the media refer more to YMAB or CRDL? In the previous week, Y-mAbs Therapeutics had 3 more articles in the media than Cardiol Therapeutics. MarketBeat recorded 3 mentions for Y-mAbs Therapeutics and 0 mentions for Cardiol Therapeutics. Y-mAbs Therapeutics' average media sentiment score of 1.22 beat Cardiol Therapeutics' score of 0.00 indicating that Y-mAbs Therapeutics is being referred to more favorably in the media. Company Overall Sentiment Y-mAbs Therapeutics Positive Cardiol Therapeutics Neutral Which has more risk & volatility, YMAB or CRDL? Y-mAbs Therapeutics has a beta of 0.54, suggesting that its share price is 46% less volatile than the S&P 500. Comparatively, Cardiol Therapeutics has a beta of 1.03, suggesting that its share price is 3% more volatile than the S&P 500. Do analysts recommend YMAB or CRDL? Y-mAbs Therapeutics currently has a consensus target price of $9.62, suggesting a potential upside of 12.21%. Cardiol Therapeutics has a consensus target price of $8.00, suggesting a potential upside of 637.33%. Given Cardiol Therapeutics' stronger consensus rating and higher possible upside, analysts clearly believe Cardiol Therapeutics is more favorable than Y-mAbs Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Y-mAbs Therapeutics 2 Sell rating(s) 8 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.80Cardiol Therapeutics 0 Sell rating(s) 0 Hold rating(s) 2 Buy rating(s) 1 Strong Buy rating(s) 3.33 SummaryCardiol Therapeutics beats Y-mAbs Therapeutics on 9 of the 16 factors compared between the two stocks. Get Cardiol Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for CRDL and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding CRDL and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart CRDL vs. The Competition Export to ExcelMetricCardiol TherapeuticsMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$90.83M$2.52B$5.75B$9.85BDividend YieldN/A48.51%6.66%4.49%P/E Ratio-3.1922.4482.7926.52Price / SalesN/A524.15499.49162.43Price / CashN/A26.3325.7028.92Price / Book10.856.8210.786.50Net Income-$26.77M$32.94M$3.28B$266.34M7 Day Performance-0.46%-0.49%-0.42%-1.25%1 Month Performance-15.23%5.06%6.47%3.30%1 Year Performance-43.78%-1.77%49.47%23.59% Cardiol Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)CRDLCardiol Therapeutics2.0764 of 5 stars$1.09-0.5%$8.00+637.3%-42.6%$90.83MN/A-3.1920YMABY-mAbs Therapeutics3.0635 of 5 stars$8.52-0.1%$9.62+12.9%-38.2%$387.59M$87.68M-17.04150Positive NewsShort Interest ↓VIGLVigil Neuroscience1.4752 of 5 stars$8.05flat$10.80+34.2%N/A$383.91MN/A-3.9340ATXSAstria Therapeutics2.3259 of 5 stars$6.42-5.4%$29.00+351.7%-39.0%$383.19MN/A-3.1930News CoverageFULCFulcrum Therapeutics1.0062 of 5 stars$6.41-6.8%$7.57+18.1%-19.5%$372.15MN/A-5.25100News CoveragePositive NewsABEOAbeona Therapeutics4.3687 of 5 stars$7.01-3.0%$19.50+178.2%+27.3%$370.74M$3.50M10.0190INBXInhibrx Biosciences1.4444 of 5 stars$25.04+0.2%N/A+74.3%$362.13M$1.40M-2.37166Positive NewsADCTADC Therapeutics2.7354 of 5 stars$3.09-3.0%$7.75+151.2%+20.3%$357.75M$70.84M-1.96310Short Interest ↓CTMXCytomX Therapeutics4.2392 of 5 stars$2.00-5.7%$5.75+187.5%+89.3%$349.61M$138.10M3.57170ALDXAldeyra Therapeutics2.4906 of 5 stars$5.77-0.7%$9.50+64.6%+0.7%$347.99MN/A-6.7910News CoveragePositive NewsBNTCBenitec Biopharma1.6749 of 5 stars$13.21+1.7%$26.00+96.8%+54.9%$340.99M$80K-8.7520News CoverageGap Down Related Companies and Tools Related Companies YMAB Alternatives VIGL Alternatives ATXS Alternatives FULC Alternatives ABEO Alternatives INBX Alternatives ADCT Alternatives CTMX Alternatives ALDX Alternatives BNTC Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:CRDL) was last updated on 9/4/2025 by MarketBeat.com Staff From Our PartnersThis Massive Market is Ripe for Disruption by this NasdaqFanatics Hit $31B. This Nasdaq Company Is Building the Next Wave Fanatics built a merch empire by owning th...i2i Marketing Group, LLC | SponsoredWhat's the Best Way to Lower RMD Taxes?Turning 73 triggers a key IRS rule: you must begin taking required minimum distributions (RMDs) from certain r...SmartAsset | SponsoredThe End of Elon Musk…?The End of Elon Musk? Don't make him laugh. Jeff Brown has been hearing this same tired story for years, an...Brownstone Research | SponsoredMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | Sponsored“Fed Proof” Your Bank Account with THESE 4 Simple StepsStarting as soon as a few months from now, the United States government will make a sweeping change to bank ac...Weiss Ratings | SponsoredFree: The Crypto Summit That Could Change Your Life27 industry leaders share urgent market intel (free access)... For a very limited time, you can claim your ...Crypto 101 Media | Sponsored2013 Bitcoin miner reveals his trading system (free)While everyone else is gambling on meme coins or chasing the next "100x moonshot," our members are systematica...Crypto Swap Profits | Sponsored“Shadow Group” in Washington, DC Could Crash MarketNew Amazon Crisis Could Tank U.S. Stock Market A new panic is halting AI projects at Amazon and could split...Altimetry | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Cardiol Therapeutics Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Cardiol Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free CRDL Stock Alerts